- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03827772
Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis- Assessment of Impact on Prognosis and Short-term Outcome
Alcoholic liver disease has become one of the foremost causes of chronic liver disease across the world, and a cause of considerable morbidity and mortality. Alcoholic steatohepatitis is an entity in this broad spectrum, with severe alcoholic hepatitis transitioning to acute on chronic liver failure carrying a one month mortality of as high as 20 to 50%.
The current management guidelines for severe alcoholic hepatitis show benefit with prolonged alcohol abstinence, nutritional support, the use of corticosteroids, pentoxifylline or N-acetyl cysteine (NAC) and early liver transplantation. However, major studies and meta-analyses have demonstrated that these interventions, with the exception of early liver transplantation, do not improve mortality rates to the level of statistical significance. Owing to the high short term mortality associated with severe alcoholic hepatitis, the inadequacy of a treatment that could significantly impact this short term mortality, and the limited applicability of early liver transplantation, a study on newer modalities of treatment is warranted.
The role that human gut microbiota plays in health and disease is receiving considerable attention. Targeting intestinal dysbiosis, a phenomenon found to be intricately linked with the causation of alcoholic hepatitis, could provide insights into novel therapeutic strategies.
Fecal microbiota transplantation is a novel approach that has gained widespread acceptance in in the management of recurrent severe Clostridium difficile infection. It's role is also being studied in other diseases where an association with gut dysbiosis has been found, such as in inflammatory bowel disease and irritable bowel syndrome. The role of FMT has also been studied in liver diseases such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis and primary sclerosing cholangitis. In this process, a diseased recipient is transferred fecal material containing the microflora of a healthy individual. It limits the colonization of pathogens, inducing colonization resistance, affects microbiota composition in the gut, as well as metabolism in the microbial pathogens. FMT helps alleviate gut dysbiosis and restores gut microbial diversity.
Our aim is to evaluate the role of FMT on short term survival and improvement in scores of prognostic significance (CTP, MELD, MELDNa, mDF) in patients with severe alcoholic hepatitis.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Radha K Dhiman, DM
- Phone Number: 7087009337
- Email: rkpsdhiman@hotmail.com
Study Locations
-
-
-
Chandigarh, India, 160012
- Recruiting
- Postgraduate Institute of Medical Education and Research
-
Contact:
- Radha K Dhiman, DM
- Phone Number: 7087009337
- Email: rkpsdhiman@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Severe alcoholic hepatitis will be defined as proposed by the American College of Gastroenterology
- Rapid development or worsening of jaundice and liver-related complications with serum total bilirubin more than 3 milligrams per decilitre.
- Aspartate aminotransferase and alanine aminotransferase elevated to more than one and half times the upper limit of normal, but less than 400 IU per litre, with AST to ALT ratio over 1.5.
- Documentation of persistent heavy alcohol use until 8 weeks before onset of symptoms.
- Alcohol Consumption in female over 40 grams per day for at least 6 months and in males over 60 grams per day for at least 6 months.
- Maddrey's Discriminant Function Score of more than 32 OR
- A patient of alcoholic hepatitis who will present with grade 1 or 2 of hepatic encephalopathy.
Exclusion Criteria:
- Intestinal paralysis, lack of bowel sounds, intestinal perforation.
- Uncontrolled infections.
- Uncontrolled upper gastrointestinal bleeding.
- Grade 3,4 hepatic encephalopathy.
- Hepatic or extrahepatic malignancy.
- Maddrey's Discriminant Function (mDF) >90 or MELD>30.
- Autoimmune hepatitis, Wilson's disease, suspected drug induced liver injury.
- Patients who are aged >60 years
- WBC count <1000 cells/mm3
- Pregnancy or nursing.
- Human Immunodeficiency Virus (HIV), HBV, HCV infection.
- Patient's unwillingness to participate in the study.
- Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Arm: Fecal microbiota transplantation
30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
|
30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
|
Other: Control Arm
Nutritional supplementation, supportive management
|
Nutritional supplementation, supportive management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Survival
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement in CTP (Child Turcotte Pugh Score)
Time Frame: 3 months
|
3 months
|
Improvement in MELD score
Time Frame: 3 months
|
3 months
|
Improvement in MELDNa score
Time Frame: 3 months
|
3 months
|
Improvement in CLIF SOFA score
Time Frame: 3 months
|
3 months
|
Improvement in mDF
Time Frame: 3 months
|
3 months
|
Changes in inflammatory markers (IL1b, IL6, TNF α) pre and post FMT,
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Digestive System Diseases
- Alcohol-Related Disorders
- Substance-Related Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Liver Diseases
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Liver Diseases, Alcoholic
- Alcohol-Induced Disorders
- Hepatitis
- Hepatitis A
- Hepatitis, Alcoholic
Other Study ID Numbers
- PGIMER Hepatology
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Alcoholic Hepatitis
-
HepQuant, LLCWithdrawnSevere Alcoholic HepatitisUnited States
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruiting
-
Institute of Liver and Biliary Sciences, IndiaUnknownSevere Alcoholic HepatitisIndia
-
Vital Therapies, Inc.TerminatedSevere Acute Alcoholic HepatitisUnited States, Spain, United Kingdom, Germany
-
CHU de ReimsCompletedSevere Alcoholic HepatitisFrance
-
Institute of Liver and Biliary Sciences, IndiaCompletedSevere Alcoholic HepatitisIndia
-
Saint Vincent's Hospital, KoreaUnknownSevere Alcoholic Hepatitis
-
University Hospital, LilleRecruitingAlcoholic Liver Disease | Severe Alcoholic Hepatitis | Alcoholic CirrhosisFrance
-
Hospital General de MexicoCompleted
-
Erasme University HospitalCompletedSevere Alcoholic HepatitisBelgium, France
Clinical Trials on Fecal Microbiota Transplantation
-
Madhusudan (Madhu) Grover, MBBSRecruiting
-
Medical University of GrazBristol-Myers SquibbTerminatedMalignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota TransplantationAustria
-
Children's Mercy Hospital Kansas CityUniversity of Pittsburgh; Stanford UniversityCompletedUlcerative Colitis (UC) | Inflammatory Bowel Diseases (IBD) | Crohn's Disease (CD)United States
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityNot yet recruitingAttention-deficit/Hyperactivity DisorderChina
-
The Second Hospital of Nanjing Medical UniversityNot yet recruiting
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityRecruiting
-
The Second Hospital of Nanjing Medical UniversityRecruitingCancer | Intestinal ComplicationsChina
-
The First Affiliated Hospital of Nanchang UniversityCompletedAcute Pancreatitis | Intestinal Bacteria Flora Disturbance | Fecal Microbiota Transplantation | Intestinal DysfunctionChina
-
The Second Hospital of Nanjing Medical UniversityWithdrawnCOVID-19 Complicated With Refractory Intestinal InfectionsChina
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingAllogeneic Hematopoietic Stem CellUnited States